Lack of Clinically Relevant Pharmacokinetic Drug-Drug Interaction between Norgestimate/Ethinyl Estradiol and Pangenotypic HCV NS5A Inhibitor GS-5816 in HCV-Uninfected Female Subjects

被引：0

作者：

Mogalian, Erik ^{[1
]}

Brainard, Diana M. ^{[1
]}

McNally, John ^{[1
]}

Shen, Gong ^{[1
]}

Cuvin, Jennifer ^{[1
]}

Mathias, Anita ^{[1
]}

机构：

[1] Gilead Sci Inc, Foster City, CA 94404 USA

来源：

HEPATOLOGY | 2014年 / 60卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

1998

引用

页码：1173A / 1173A

页数：1

共 12 条

[1] THE PHARMACOKINETICS OF GS-5816, A PANGENOTYPIC HCV-SPECIFIC NS5A INHIBITOR, IN HCV-UNINFECTED SUBJECTS WITH SEVERE RENAL IMPAIRMENT
Mogalian, E.
Mathias, A.
Brainard, D.
Shen, G.
McNally, J.
Sajwani, K.
Robson, R.
Ries, D.
Lasseter, K.
Marbury, T.
JOURNAL OF HEPATOLOGY, 2015, 62 : S590 - S591
[2] Lack of a Clinically Important Pharmacokinetic Interaction between Norgestimate/Ethinyl Estradiol and Sofosbuvir (SOF) or Ledipasvir (LDV) in HCV-Uninfected Female Subjects
German, Polina
Moorehead, Lisa
Pang, Phil S.
Vimal, Mona
Mathias, Anita
HEPATOLOGY, 2013, 58 : 433A - 433A
[3] THE PHARMACOKINETICS OF GS-5816, A PAN-GENOTYPIC HCV NS5A INHIBITOR, IN HCV-UNINFECTED SUBJECTS WITH MODERATE AND SEVERE HEPATIC IMPAIRMENT
Mogalian, E.
Mathias, A.
Brainard, D.
McNally, J.
Moorehead, L.
Hernandez, M.
Perry, R.
Curtis, C.
Lawitz, E.
Lasseter, K.
Marbury, T.
JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S317 - S317
[4] Lack of a Clinically Important Pharmacokinetic Interaction Between Sofosbuvir or Ledipasvir and Hormonal Oral Contraceptives Norgestimate/Ethinyl Estradiol in HCV-Uninfected Female Subjects
German, P.
Moorehead, L.
Pang, Phillip
Vimal, M.
Mathias, A.
JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 54 (11): : 1290 - 1298
[5] Lack of a Clinically Significant Pharmacokinetic Drug-Drug Interaction between Sofosbuvir and GS-5816 in Healthy Volunteers
Mogalian, Erik
German, Polina
Brainard, Diana M.
Link, John O.
McNally, John
Han, Lingling
Kearney, Brian P.
HEPATOLOGY, 2013, 58 : 431A - 431A
[6] Drug-Drug Interaction Studies between HCV Antivirals Sofosbuvir and GS-5816 and HIV Antiretrovirals
Mogalian, Erik
Stamm, Luisa M.
Osinusi, Anu
Shen, Gong
Sajwani, Karim
McNally, John
Mathias, Anita
HEPATOLOGY, 2015, 62 : 1310A - 1310A
[7] Lack of Pharmacokinetic Interaction Between HCV Protease Inhibitor MK-5172 and HCV NS5A Inhibitor Daclatasvir in Healthy Volunteers
Yeh, Wendy W.
Fraser, Iain P.
Bifano, Marc
Caro, Luzelena
Talaty, Jennifer E.
Guo, Zifang
McCarthy, Jennifer M.
Youngberg, Stephen P.
Butterton, Joan R.
HEPATOLOGY, 2013, 58 : 430A - 431A
[8] PHARMACOKINETIC (PK) DRUG-DRUG INTERACTION BETWEEN SAMATASVIR (IDX719), A PAN-GENOTYPIC NS5A INHIBITOR, AND SIMEPREVIR IN HEALTHY VOLUNTEERS AND HCV-INFECTED SUBJECTS
Zhou, X. J.
Donovan, E.
Chen, J.
van Heeswijk, R.
Sullivan-Bolyai, J. Z.
Mayers, D.
JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S495 - S495
[9] Use of Multiple Probes to Assess Transporter- and Cytochrome P450-Mediated Drug-Drug Interaction Potential of the Pangenotypic HCV NS5A Inhibitor Velpatasvir
Mogalian, Erik
German, Polina
Kearney, Brian P.
Yang, Cheng Yong
Brainard, Diana
McNally, John
Moorehead, Lisa
Mathias, Anita
CLINICAL PHARMACOKINETICS, 2016, 55 (05) : 605 - 613
[10] Use of Multiple Probes to Assess Transporter- and Cytochrome P450-Mediated Drug–Drug Interaction Potential of the Pangenotypic HCV NS5A Inhibitor Velpatasvir
Erik Mogalian
Polina German
Brian P. Kearney
Cheng Yong Yang
Diana Brainard
John McNally
Lisa Moorehead
Anita Mathias
Clinical Pharmacokinetics, 2016, 55 : 605 - 613

← 1 2 →